Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Tonix Pharmaceuticals appoints industry veteran Ganesh Kamath as Head of Market Access
Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025. The biotechnology company said Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix.
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valuation, potential dilution, and uncertainty around commercialization and pricing. Tonmya's novel formulation and high unmet need could drive strong adoption, with revenue potential of $219M–$365M annually at modest market penetration.
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy
I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved market; FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue. Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage in this market.
Tonix Pharmaceuticals Holding Corp. (TNXP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tonix Pharmaceuticals Holding Corp. ever had a stock split?
Tonix Pharmaceuticals Holding Corp. Profile
| Biotechnology Industry | Healthcare Sector | Seth Lederman CEO | NASDAQ (CM) Exchange | 890260839 CUSIP |
| US Country | 81 Employees | - Last Dividend | 5 Feb 2025 Last Split | 10 May 2012 IPO Date |
Overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company dedicated to the discovery, acquisition, development, and licensing of therapeutics and diagnostics aimed at treating and preventing human diseases and alleviating suffering. Since its inception in 2007, Tonix Pharmaceuticals has been headquartered in Chatham, New Jersey. Its extensive portfolio spans immunology, rare diseases, infectious diseases, and central nervous system (CNS) product candidates, demonstrating a diverse approach to addressing critical areas of medicine.
Products and Services
- TNX-1500: A humanized monoclonal antibody targeting CD40-ligand, TNX-1500 is under development for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases within the company's immunology portfolio.
- TNX-2900: Designed for the treatment of Prader-Willi syndrome, TNX-2900 represents Tonix Pharmaceuticals' commitment to addressing rare diseases with significant unmet medical needs.
- TNX-801: As part of the infectious disease pipeline, TNX-801 is a vaccine aimed at preventing smallpox and monkeypox, showcasing the company’s efforts in combating emerging and re-emerging infectious diseases.
- TNX-1840 and TNX-1850: These live virus vaccines are based on the company's recombinant pox vaccine (RPV) platform and are in development for COVID-19, reflecting Tonix Pharmaceuticals’ adaptation to current global health challenges.
- TNX-3500: A small molecule antiviral drug, TNX-3500 is aimed at treating acute COVID-19, further contributing to the company’s infectious disease portfolio.
- TNX-102 SL: This small molecule drug serves dual purposes; it is in mid-Phase 3 development for the management of fibromyalgia and also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. This showcases the company's innovative approach in using a single molecule to target different indications.
- TNX-1900: In development for the prevention of migraine headache, TNX-1900 is part of the CNS portfolio, targeting the significant burden of neurological diseases.
- TNX-1300: A biologic designed to treat cocaine intoxication, illustrating Tonix Pharmaceuticals' dedication to addressing addiction and its complications.
Contact Information
